드러그인포 약품요약정보 - 광동마스투에스연고

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

비급여
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

엷은 황색을 띤 연고제 [제형정보 확인]

포장·유통단위

20g, 1EA

효능효과

[적응증 별 검색]

1기 및 2기 치핵, 치열, 급 ·만성 항문습진, 직장염

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]

외부에 적용시: 1일 2회 환부에 바른 후 마사지하듯 가볍게 문질러 준다.

직장내 투여시: 주입기를 이용하여 1일 2회 직장 내 삽입한다.
[제형별복약지도]

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

금기

본제 성분에 과민증의 기왕력자, 치료부위에 매독, 결핵 등의 특정 피부질환환자

신중투여

소아 및 청소년

이상반응

이 나타날 수 있다.

드물게 수포, 심울, 낙설, 구반 등을 수반한 환부의 부종이 나타날 수 있으며 드물게 넓은 부위에 걸쳐 심하게 나타날 수 있다.

[주요 이상반응정보]

상호작용

다른 약물과 병용투여시 부작용 등의 발생은 보고된 바 없다.
본제는 콘돔, 질내 피임용격막과 같은 라덱스 또는 고무제품을 약화시킬 수 있으므로 주의한다.

Off-label Usage

[조회]

Related FDA Approved Drug

기준 성분:TITANIUM DIOXIDE
ANTHELIOS 20 (AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE)
ANTHELIOS 40 (AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE)
기준 성분:LIDOCAINE HYDROCHLORIDE
AKTEN (LIDOCAINE HYDROCHLORIDE)
ALPHACAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ANESTACON (LIDOCAINE HYDROCHLORIDE)
DECADRON W/ XYLOCAINE (DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE)
DUOCAINE (BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE)
EMBOLEX (DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE)
IONTOCAINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LARYNG-O-JET KIT (LIDOCAINE HYDROCHLORIDE)
LARYNGOTRACHEAL ANESTHESIA KIT (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE VISCOUS (LIDOCAINE HYDROCHLORIDE)
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDOCAINE VISCOUS (LIDOCAINE HYDROCHLORIDE)
LIDOCATON (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIDOPEN (LIDOCAINE HYDROCHLORIDE)
LIDOSITE TOPICAL SYSTEM KIT (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
LIGNOSPAN FORTE (EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE)
LIGNOSPAN STANDARD (EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE)
LTA II KIT (LIDOCAINE HYDROCHLORIDE)
OCTOCAINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
PEDIATRIC LTA KIT (LIDOCAINE HYDROCHLORIDE)
TERRAMYCIN (LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE)
XYLOCAINE (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE 1.5% W/ DEXTROSE 7.5% (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE 4% PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE 5% W/ GLUCOSE 7.5% (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE DENTAL (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE DENTAL WITH EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
XYLOCAINE PRESERVATIVE FREE (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE VISCOUS (LIDOCAINE HYDROCHLORIDE)
XYLOCAINE W/ EPINEPHRINE (EPINEPHRINE; LIDOCAINE HYDROCHLORIDE)
ZINGO (LIDOCAINE HYDROCHLORIDE)
기준 성분:BUFEXAMAC
기준 성분:BISMUTH SUBGALLATE

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
BIT 약효분류	혈관강화제, 정맥류 치료제, 치질약(Capillary stabilizer, Phlebitis, Varicose veins, Hemorrhoidal)
ATC 코드	Local anesthetics / C05AD [코드분류상세설명] [ATC코드예측]
복지부분류코드	256 (치질용제 )
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	비급여 [상병코드조회] [질병코드집 다운로드]
제품성상	엷은 황색을 띤 연고제 [제형정보 확인]
포장·유통단위	20g, 1EA

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : B등급

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

신장애, 간장애시
용량조절

유료정보입니다.

Pharmacokinetics

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

제형별 복약지도

[연고]

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	Lidocaine에 대한 독성정보 : 정보보기 Titanium에 대한 독성정보 : 정보보기 Titanium dioxide에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Lidocaine에 대한 Mechanism_Of_Action 정보 Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
Pharmacology	Lidocaine에 대한 Pharmacology 정보 Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide.
Metabolism	Lidocaine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)
Protein Binding	Lidocaine에 대한 단백결합 정보 60-80%
Half-life	Lidocaine에 대한 반감기 정보 109 minutes
Absorption	Lidocaine에 대한 Absorption 정보 Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent.
Pharmacokinetics	Lidocaine Hydrochloride의 약물동력학자료 효과발현시간 (1회 bolus 용량으로서) : 45-90초 작용지속시간 : 10-25분 분포 (Vd) : 많은 요인에 따라 변화되며, 울혈성 심부전과 간질환에서는 분포용적이 감소됨 단백결합 : 60-80%, α₁-acid glycoprotein과 결합 대사 : 간에서 90% 대사 활성형 대사체인 monoethylglycinexylidide(MEGX)와 glycinexylidide(GX)가 축적되어 중추신경계 독성을 유발할 수 있다. 반감기 (biphasic) : 울혈성 심부전, 간질환, 쇼크, 중증의 신질환에서 증가 초기 : 7-30분 말기 : 영아, 미숙아 : 3.2시간, 성인 : 1.5-2시간 Bufexamac의 약물동력학자료 흡수 : 경구로 투여했을 경우, 빠르고, 거의 100 %흡수된다. 국소제제의 경우, 매개체에 따라 다르다. 대사 : 포합반응을 통해 대사되어 BPAA(p-n-Butoxyphenylacetic acid), HPA(p-hydroxyphenylacetic acid)로 대사된다. 신배설 : 대사체 75%, 모약물 1% 모약물의 elimination half life는 3시간이다.
Biotransformation	Lidocaine에 대한 Biotransformation 정보 Primarily hepatic.
Toxicity	Lidocaine에 대한 Toxicity 정보 The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
Drug Interactions	Bismuth에 대한 Drug_Interactions 정보 Acetazolamide The salicylate at high dose increases the effect of the carbonic anhydrase inhibitorsAcetohexamide The salicylate increase the effect of sulfonylureaMethotrexate The salicylate increase the effect and toxicity of methotrexateAnisindione The salicylate increase effect of anticoagulantBetamethasone The corticosteroid decreases the effect of salicylatesChlorpropamide The salicylate increase the effect of sulfonylureaCortisone acetate The corticosteroid decreases the effect of salicylatesDemeclocycline Formation of non-absorbable complexesDexamethasone The corticosteroid decreases the effect of salicylatesDichlorphenamide The salicylate at high dose increases the effect of the carbonic anyhydrase inhibitorsDicumarol The salicylate increase effect of anticoagulantValproic Acid The salicylate increase the effect of valproic acidDoxycycline Formation of non absorbable complexesFludrocortisone The corticosteroid decreases the effect of salicylatesGliclazide The salicylate increase the effect of sulfonylureaGlipizide The salicylate increase the effect of sulfonylureaGlisoxepide The salicylate increase the effect of sulfonylureaGlibenclamide The salicylate increase the effect of sulfonylureaGlycodiazine The salicylate increase the effect of sulfonylureaHydrocortisone The corticosteroid decreases the effect of salicylatesInsulin The salicylate increase the effect of insulinInsulin-aspart The salicylate increase the effect of insulinInsulin-detemir The salicylate increase the effect of insulinInsulin-glargine The salicylate increase the effect of insulinInsulin-glulisine The salicylate increase the effect of insulinInsulin-lispro The salicylate increase the effect of insulinMethacycline Formation of non absorbable complexesMethazolamide The salicylate at high dose increases the effect of the carbonic anhydrase inhibitorsMethylprednisolone The corticosteroid decreases the effect of salicylatesMinocycline Formation of non-absorbable complexesAcenocoumarol The salicylate increases effect of anticoagulantOxytetracycline Formation of non-absorbable complexesParamethasone The corticosteroid decreases the effect of salicylatesPrednisolone The corticosteroid decreases the effect of salicylatesPrednisone The corticosteroid decreases the effect of salicylatesProbenecid The salicylate decreases the uricosuric effect of probenecidSulfinpyrazone The salicylate antagonizes the uricosuric effect of sulfinpyrazoneTetracycline Formation of non-absorbable complexesTolazamide The salicylate increase the effect of sulfonylureaTolbutamide The salicylate increase the effect of sulfonylureaTriamcinolone The corticosteroid decreases the effect of salicylatesWarfarin The salicylate increases effect of anticoagulant Lidocaine에 대한 Drug_Interactions 정보 Not Available
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	Bismuth에 대한 Food Interaction 정보 Take without regard to meals. Lidocaine에 대한 Food Interaction 정보 Not Available
Drug Target	[Drug Target]
Description	Bismuth에 대한 Description 정보 Bismuth compounds are widely used for the treatment of peptic ulcers and Helicobacter pylori infections. It has been suggested that enzyme inhibition plays an important role in the antibacterial activity of bismuth towards this bacterium. Bismuth thiols appear to act on bacterial ureases. Lidocaine에 대한 Description 정보 A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]
Dosage Form	Bismuth에 대한 Dosage_Form 정보 Dressing TopicalLiquid OralLiquid SublingualSolution / drops OralSuppository RectalSuspension OralTablet Oral Lidocaine에 대한 Dosage_Form 정보 Aerosol TopicalAerosol, metered TopicalCream TopicalGel TopicalJelly TopicalJelly UrethralLiquid BuccalLiquid DentalLiquid InfiltrationLiquid IntravenousLiquid OralLiquid TopicalLotion TopicalOintment TopicalSolution InfiltrationSolution IntramuscularSolution IntravenousSolution OralSolution TopicalSpray TopicalSwab Topical
Drug Category	Bismuth에 대한 Drug_Category 정보 Antidiarrheals Lidocaine에 대한 Drug_Category 정보 AnestheticsAnesthetics, LocalAnti-Arrhythmia AgentsAntiarrhythmic Agents
Smiles String Canonical	Bismuth에 대한 Smiles_String_canonical 정보 O.O=C1O[Bi]OC2=CC=CC=C12 Lidocaine에 대한 Smiles_String_canonical 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
Smiles String Isomeric	Bismuth에 대한 Smiles_String_isomeric 정보 O.O=C1O[Bi]OC2=CC=CC=C12 Lidocaine에 대한 Smiles_String_isomeric 정보 CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
InChI Identifier	Bismuth에 대한 InChI_Identifier 정보 InChI=1/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+2;/p-2/fC7H4O3.Bi.H2O/h8h;;/q-2;m;/rC7H4BiO3.H2O/c9-7-5-3-1-2-4-6(5)10-8-11-7;/h1-4H;1H2 Lidocaine에 대한 InChI_Identifier 정보 InChI=1/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)/f/h15H
Chemical IUPAC Name	Bismuth에 대한 Chemical_IUPAC_Name 정보 3,5-dioxa-4$l^{2}-bismabicyclo[4.4.0]deca-1(10),6,8-trien-2-one hydrate Lidocaine에 대한 Chemical_IUPAC_Name 정보 2-diethylamino-N-(2,6-dimethylphenyl)acetamide
Drug-Induced Toxicity Related Proteins	DOCA 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Aquaporin-2 Drug:DOCA Toxicity:hypertension. [바로가기] LIDOCAINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:glucose-regulated protein Drug:lidocaine Toxicity:intestinal disorder. [바로가기] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:C-reactive protein Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기] Replated Protein:Alpha-1-acid glycoprotein Drug:lidocaine Toxicity:lidocaine tolerance. [바로가기] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:Alkaline phosphatase Drug:lidocaine Toxicity:fever. [바로가기] Replated Protein:Gamma-glutamyltranspeptidase Drug:lidocaine Toxicity:lidocaine induced hepatitis. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보